Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Status:
Active, not recruiting
Trial end date:
2023-02-15
Target enrollment:
Participant gender:
Summary
This pilot trial studies the side effects and how well imiquimod and pembrolizumab work in
treating patients with stage IIIB-IV melanoma. Imiquimod may stimulate the immune system.
Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells
to grow and spread. Giving imiquimod and pembrolizumab may work better at treating melanoma.